Scilex Holding announced that according to prescription data from Symphony Health, ZTlido is the most prescribed non-opioid, branded pain treatment prescribed by pain specialists. Total ZTlido NRx market share grew to 14.2% in October 2023, compared to 11.8% in October 2022 according to prescription data from Symphony Health.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SCLX:
- Scilex Holding Company Announces Results from Market Research with Rheumatologists Reveal a High Degree of Interest in Gloperba® as a Liquid Colchicine Formulation Designed for Precision Dosing
- Scilex announces results from market research on Gloperba
- Scilex Holding Company announces major pharmacy initiative with the national leading pharmacy chain to stock ELYXYB® in most of their stores throughout the U.S.
- Scilex says national pharmacy chain to stock ELYXYB in most U.S. stores
- Scilex announces expanded access to ELYXYB